Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in high-risk oral premalignant lesions
2020-000295-38Phase 2Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in oral premalignancies, sponsored by ASST Spedali Civili di Brescia. Primary endpoints: Reversion of malignant transformation risk and Reversal of loss of heterozygosity status. Started Jun 2021; status: completed.
02
Drugs
avelumab
03
Conditions
oral premalignancies
Beyond the preview
Go deeper on 2020-000295-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000295-38.